New treatment options for colorectal cancer

被引：31

作者：

Erlichman, C ^{[1
]}

Sargent, DJ ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN 55905 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 351卷 / 04期

关键词：

D O I：

10.1056/NEJMe048151

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：391 / 392

页数：2

共 14 条

[1] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[2]

Douillard JY, 2000, LANCET, V355, P1372

[3] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[4] Developing inhibitors of the epidermal growth factor receptor for cancer treatment [J].

Grünwald, V ;

Hidalgo, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :851-867

[5] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[6] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[7]

Prewett MC, 2002, CLIN CANCER RES, V8, P994

[8] Erbitux trial flawed from the beginning, committee finds [J].

Randal, J .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (24) :1824-1825

[9] Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial [J].

Rothenberg, ML ;

Oza, AM ;

Bigelow, RH ;

Berlin, JD ;

Marshall, JL ;

Ramanathan, RK ;

Hart, LL ;

Gupta, S ;

Garay, CA ;

Burger, BG ;

Le Bail, N ;

Haller, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2059-2069

[10]

SALTZ L, 2001, 37 ANN M AM SOC CL 1, V20, P3

← 1 2 →